BI_PharmAccess_launch_digital_healthcare_program BI_PharmAccess_launch_digital_healthcare_program Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
cat feline diabetes medication treatment fda approval cat feline diabetes medication treatment fda approval Boehringer Ingelheim receives FDA approval for SENVELGO®
Closing healthcare gaps with continued vaccination campaigns Closing healthcare gaps with continued vaccination campaigns How we continue combating rabies through collaborative efforts and the use of drone delivery in rural Kenya.
Winners of BVDzero Scholarship Programme Winners of BVDzero Scholarship Programme Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
Launch of BVDzero scholarship for veterinary students Launch of BVDzero scholarship for veterinary students Launch of BVDzero scholarship for veterinary students globally
expanded-collaboration-MD-Anderson expanded-collaboration-MD-Anderson The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
university-of-medical-excellence-harvard university-of-medical-excellence-harvard A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
DiaTEC new purification technology Ingelvac CircoFLEX DiaTEC new purification technology Ingelvac CircoFLEX Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®
Survodutide Phase III study weight loss Survodutide Phase III study weight loss Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
digital_leader_award_2020 digital_leader_award_2020 Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
additional-investment-in-Lyon-Jonage additional-investment-in-Lyon-Jonage Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
Phase 1 start for novel triple agonist obesity treatment Phase 1 start for novel triple agonist obesity treatment Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
Approval for Aservo EquiHaler equine asthma therapy Approval for Aservo EquiHaler equine asthma therapy Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
EMA authorization for Reprocyc ParvoFLEX EMA authorization for Reprocyc ParvoFLEX Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
Outlook for Partnering in Animal Health 2024 Outlook for Partnering in Animal Health 2024 Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
On the road with sanitation workers in India On the road with sanitation workers in India Exhaust fumes, heat, work and traffic accidents. Overcoming all these odds, the sanitation workers in India fight a daily battle.
Purpose Hero Video Purpose Hero Video Begin a career with purpose and explore careers at Boehringer Ingelheim.
Groundbreaking oncology research zongertinib Groundbreaking oncology research zongertinib Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Green Chemistry Green Chemistry Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.
cat feline diabetes medication treatment eu approval cat feline diabetes medication treatment eu approval Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
Experiences of living with cancer Experiences of living with cancer We know from speaking with people living with cancer and their loved ones, that it’s often the small moments that can be the most significant.
2024 half year results innovation progress 2024 half year results innovation progress First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Circular economy Circular economy Boehringer Ingelheim strives to use resources for as long as possible, process them for reuse or recycle them.
CHMP_opinion_Nintedanib_SSc-ILD CHMP_opinion_Nintedanib_SSc-ILD Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Partnering with Boehringer Ingelheim MAY 2024 CORP.pdf Partnering with Boehringer Ingelheim MAY 2024 CORP.pdf